US Patent Issued to MiNK Therapeutics on Aug. 19 for "T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof" (Swiss, Dutch, American, French Inventors)

ALEXANDRIA, Va., Aug. 20 -- United States Patent no. 12,391,741, issued on Aug. 19, was assigned to MiNK Therapeutics Inc. (New York).

"T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof" was invented by Marc van Dijk (Bosch en Duin, Netherlands), Ekaterina Vladimirovna Breous-Nystrom (Basel, Switzerland), Alessandra Franchino (Basel, Switzerland), Sebastien Lalevee (Saint Louis, France), Arthur Andrew Hurwitz (Bedford, Mass.), Mark Adrian Exley (Brookline, Mass.) and Benjamin Jacob Wolf (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs tha...